Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
  • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations

Definitions

• the invention refers to a cosmetic composition and a method for reducing the ageing processes of skin and/or treating the pathological lesions of skin.
• the invention refers to a cosmetic composition
• a cosmetic composition comprising a hydroximic acid derivative of the formula
• R represents a hydrogen atom or a C, _ c alkyl group
• R stands for a hydrogen atom, a C,_ 5 alkyl group, a C 3 ⁇ cycloalkyl group or a phenyl group optionally substituted by a hydroxy or a phenyl group, or R 1 and R2 together with the nitrogen atom they are attached to form a 5 to 8 membered ring optionally containing one or more further nitrogen, oxygen or sulfur atom(s) and said ring can be condensed with another alicyclic or heterocyclic ring, preferably a benzene, naphthalene, quinoline, iso ⁇ quinoline, pyridine or pyrazoline ring, furthermore, if desired and chemically possible, the nitrogen and/or sulfur heteroato ( s ) are present in the form of an oxide or dioxide,
• R means a hydrogen atom, a phenyl group, a naphthyl group or a pyridyl group wherein said groups can be susbtituted by one or more halo atom(s) or C, . alkoxy group(s) ,
• Y is a hydrogen atom, a hydroxy group, a C, _. alkoxy group optionally substituted by an amino group, a C ? _ 4 polyalkenyloxy group containing 1 to 6 double bond(s), a C 1, — ⁇ _D c alkanoyl group, a C 3-. ⁇ n 2 alk -.enoyl group or a group of the formula R -C00- wherein R represents a C_ -. 0 polyalkenyl group containing 1 to 6 double bond(s), X stands for a halo atom, an amino group, a C, _. alkoxy group, or X forms with B an oxygen atom, or X and Y together with the carbon atoms they are attached to and the -NR-0-CH_- group being between said carbon atoms form a ring of the formula
• Z represents an oxygen atom or a nitrogen atom
• R stands for a hydrogen atom or R forms with B a chemical bond
• A is a C, . alkylene group or a chemical bond or a group of the formula
• R represents a hydrogen atom, a C, _ alkyl group, a C 3 _ Q cycloalkyl group or a phenyl group optionally substituted by a halo atom, a C, . alkoxy group or a C, 5 alkyl group,
• R 5 stands for a hydrogen atom, a C, alkyl group or a phenyl group, has a value of 0, 1 or 2, n has a value of 0, 1 or 2, or a physiologically acceptable acid addition salt thereof as the active ingredient.
• the human skin is a natural target of light radiation having several known pleasant and unpleasant effects such as sunburn and carcinogenesis. Due to the ultraviolet radiation, free radicals (for example hydroxy -4-
• radicals or nascent oxygen form in the skin. Such free radicals can injure the DNA and contribute to the ageing of the skin.
• free radicals may also form in biochemical processes.
• free radicals of oxygen origin such as superoxide anion, perhydroxy or hydroxy radical, hydrogen peroxide etc. may form.
• Free radicals having powerful oxidizing effect can injure the membrane by oxidizing the unsaturated fatty acid components of the membrane (peroxidization of lipids) on the one hand, and reactive aldehydes are formed during the oxidization on the other hand.
• the increased intake of calcium leads to cell death, and pathological processes are started due to the presence of the reactive aldehydes:
• the natural protective mechanisms against ultraviolet radiation include bronzing due to the formation of melanin, DNA repair mechanism etc.
• the deficiency of a protective mechanism such as the damage of the DNA repair and consequently the loss of the correction of the DNA injuries caused by the ultraviolet rays leads to the early ageing of skin or perhaps to a disease called xeroderma pigmentosum that can be accompanied by the development of a malignant tumor.
• Sunburn spots caused by bronzing in the early childhood are healed leaving an extended scar.
• various malignant tumors e.g. melanoma, cerato-acanthoma, basalioma, sarcoma
• hydroximic acid derivatives of the formula I are known. HU-P No. 177 578 and its equivalent US-P No. 4,308,399 describe hydroximic acid derivatives within the compounds of the formula I suitable for the treatment of diabetic angiopathy.
• HU-P No. 207 988 and its equivalent E-P No. 417 210 also describe hydroximic acid halides within the formula I having a selective beta-blocking effect, thus, being suitable for the treatment of diabetic angiopathy.
• the aim of the invention is to provide a composition suitable for reducing the ageing processes of skin and/or treating the pathological lesions of skin.
• composition comprising a hydroximic acid derivative of the formula I or a physiologically acceptable acid addition salt thereof as the active ingredient.
• composition a cosmetic composition, or a medical cosmetic composition or a pharmaceutical composition is meant which is suitable, in the first place, for local treatment, and is applied to the skin surface in a conventional manner.
• composition of the invention comprises a hydroximic acid derivative of the formula I or a physiologically acceptable acid addition salt thereof as the active ingredient in admixture with one or more conventional carrier(s) of cosmetic compositions.
• a C, 5 alkyl group is, for example, a methyl, ethyl, n-propyl, isopropyl, n-butyl or n- -pentyl group, preferably a methyl or an ethyl group.
• a C 3 8 c y cloa * Lk Y-'* group is, for example, a cyclopropyl, cyclopentyl, cyclohexyl, cyclo- heptyl or cyclooctyl group, preferably a cyclopentyl or a cyclohexyl group.
• a 5 to 8 membered ring containing one or more heteroatom(s) can be, for example, a pyrrole, pyrazole, imidazole, oxazole, thiazole, pyridine, pyridazine, pyrimidine, piperazine, morpholine, indole, quinoline etc. ring.
• a C, _ 4 alkoxy group is, for example, a methoxy, ethoxy, n-propoxy, tert. -butoxy, n-pentoxy, decyloxy, dodecyloxy, octadecyloxy etc. group.
• a C, _,. alkanoyl group is, for example, a formyl, acetyl, propionyl, butiryl, caproyl, palmityl, stearyl etc. group.
• a C-. Q alkenoyl group is, for example, an acryloyl, pentenoyl, hexenoyl, heptenoyl, octenoyl etc. group.
• a C, 4 alkylene group is, for example, a methylene, ethylene, propylene or butylene group.
• a halo atom is, for example, a fluoro, chloro, bromo or iodo atom, preferably a chloro or a bromo atom.
• Y stands for a group of the formula 7 R -COO- , it can represent, for example, a linolenoyl, linoloyl, docosahexanoyl, eicosa- pentanoyl, arachidonoyl etc. group.
• I are the acid addition salts formed with physiologically acceptable inorganic acids such as hydrochloric acid, sulfuric acid etc. or with physiologically acceptable organic acids such as acetic acid, fumaric acid, lactic acid etc.
• a preferred subgroup of the compounds of the formula I consists of the hydroximic acid derivatives of the formula
• R 1 , R2, R3, R4, R5, m and n are as stated in relation to formula I, X represents a halo atom or an amino group, Y means a hydroxy group.
• Especially preferred compounds of the formula II are those wherein R 1 and R2 together with the nitrogen atom they are attached to form a piperidino group, R stands for a pyridyl group, m and n have a value of 0, X is as defined above.
• R 1 and R2 together with the nitrogen atom they are attached to form a piperidino group R stands for a pyridyl group
• m and n have a value of 0, X is as defined above.
• preferred species are as follows:
• R 1, R2, R3 and A are as stated in relation to formula I.
• R 1, R2, R3 and A are as stated in relation to formula I, Z represents an oxygen or a nitrogen atom.
• R 1, R2, R3 and A are as stated in relation to formula I, R stands for a
• the compounds of the formula I can be prepared by the processes known from HU-P
• composition of the invention contains, in general, 0.1 to 30 % by mass, suitably 2 to 10 % by mass, preferably 4 to 5 % by mass of a hydroximic acid derivative of the formula I or a physiologically acceptable acid addition salt thereof as the active ingredient and conventional carrier(s) of the cosmetic compositions.
• compositions of the invention can be conventional cosmetic formulations suitable for the local treatment of the skin surface.
• Preferred formulations are creams, body emulsions, sun-emulsions, skin treatment foams, sprays, skin regenerating ampouls etc.
• compositions of the invention may contain, in addition to the active ingredient, the conventional carriers of cosmetic compositions generally in an amount of 70 to 99.9 % by mass.
• suitable carriers are, for example, one- or two-basic alcohols having a saturated or an unsaturated carbon chain such as cetyl alcohol, stearyl alcohol, cetyl- stearyl alcohol, oleyl alcohol, lauryl alcohol, ethylene glycol, propylene glycol, glycerol; natural fats and oils such as olive oil, avocado oil, wheat-germ oil, maize-germ oil, lanolin, cocoa-butter; higher hydro ⁇ carbons such as vaseline oil, vaseline; bee- wax; cellulose derivatives; emulgators such as sodium lauryl sulfate, fatty acid or oleic acid esters of sorbitan, fatty acid or oleic acid esters of poly(ethylene glycol )s, sorbitan ethers of fatty alcohols or oleic alcohols, poly(
• compositions of the invention are prepared by blending the ingredients thereof, in a manner known per se.
• the ingredients of the fatty phase and those of the aqueous phase are separately admixed, then the two phases are blended using a fatty phase of elevated temperature, if required.
• the active ingredient of the formula I is added, preferably in an aqueous solution, to the fatty phase or to the mixture of the other ingredients.
• the skin ageing inhibition effect of the compounds of the formula I was examined on guinea-pigs.
• the skin surface of 8 guinea- pigs was depilated, then, on both sides of
• the skin surface is protected from the damaging effects of the UV-B light by the composition of the invention and the compound of the formula I, respectively. If the skin surface is treated with the composition of the invention immediately after the irradiation, only a weak injury of the epithelium is experienced, at the most.
• a further embodiment of the invention consists of a method for reducing the ageing processes of skin and/or treating the pathological lesions of skin, said method comprising treating the affected skin surface with a cosmetically effective non-toxic amount of a hydroximic acid derivative of the formula I or a physiologically acceptable acid addition salt thereof.
• the skin surface is treated with a cosmetic composition comprising 0.1 to 30 % by mass of a hydroximic acid derivative of the formula I or a physiologically acceptable acid addition salt thereof.
• the skin surface is treated with 0-( 3-piperidino-2-hydroxy-l-propyl)pyrid- -3-ylhydroximic acid chloride or 0-( 3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxi e or a physiologically acceptable acid addition salt thereof.
• Example 1 Cream (oil/water)
• the cream consists of the following ingredients: compound "A" 4.0 % by mass cetylstearyl alcohol 7.5 % by mass stearic acid 9.0 % by mass glycerol monostearate 2.0 % by mass sodium lauryl sulfate 0.5 % by mass methyl p-hydroxybenzoate 0.1 % by mass distilled water 76.9 % by mass
• the lipophilic ingredients cetylstearyl alcohol, stearic acid and glycerol mono ⁇ stearate
• the sodium lauryl sulfate and methyl p-hydroxy ⁇ benzoate are dissolved in about 38 ml of distilled water at 60 to 65 °C, the pH of the solution is adjusted by the addition of diluted aqueous sodium hydroxide solution to a value of 9 to 10, then the aqueous solution is admixed to the mixture of the lipophilic ingredients, and the emulsion obtained is stirred until cold.
• the active ingredient is dissolved in the remaining water and the solution is admixed to the cooled cream.
• Example 2 Cream (water/oil) The cream consists of the following ingredients: compound "A" 5.0 % by mass cetylstearyl alcohol 10.0 % by mass white wax 10.0 % by mass neutral oil 35.0 % by mass
• Imwitor (R) 780 K (partial glycerides of vegetable fatty acids) 5.0 % by mass ethyl p-hydroxybenzoate 0.1 % by mass distilled water 34.9 % by mass
• Cream (water/oil)
• the cream consists of the following ingredients: compound "A” 5.0 % by mass cetylstearyl alcohol 1.5 % by mass white wax 1.5 % by mass lanalcol 2.5 % by mass cholesterol 1.0 % by mass white vaseline 43.5 % by mass sodium tetraborate 2.0 % by mass methyl p-hydroxybenzoate 0.1 % by mass distilled water 42.9 % by mass
• Moisturizing cream for night The cream consisting of the following ingredients is prepared using the method described in Example 1: compound "B" 5.0 % by mass cetyl alcohol 5.0 % by mass lanolin (anhydrous) 5.0 % by mass cocoa-butter 5.0 % by mass vaseline 5.0 % by mass vaseline oil 5.0 % by mass isopropyl miristate 1.0 % by mass isopropyl palmitate 1.0 % by mass wheat-germ oil 10.0 % by mass evening primrose oil 5.0 % by mass vitamin A 0.03% by mass vitamin E 0.05% by mass glycerol 5.0 % by mass propylene glycol 5.0 % by mass methyl p-hydroxybenzoate 0.2 % by mass perfume 0.1 % by mass water, demineralized 42.62% by mass
• the cream consisting of the following ingredients is prepared by the method described in Example 1.
• compound "B” 5.0 % by mass cetyl alcohol 5.0 % by mass lanolin (anhydrous) 5.0 % by mass vaseline 5.0 % by mass vaseline oil 5.0 % by mass isopropyl miristate 1.0 % by mass isopropyl palmitate 1.0 % by mass borage oil 4.0 % by mass peanut oil 11.0 % by mass vitamin A 0.03% by mass vitamin E 0.05% by mass glycerol 5.0 % by mass propylene glycol 5.0 % by mass methyl p-hydroxybenzoate 0.2 % by mass perfume 0.1 % by mass water, demineralized 47.62 % by mass
• the body milk consisting of the following ingredients is prepared by the method described in Example 1.
• compound "B” 4.0 % by mass stearic acid monoglyceride 2.0 % by mass cetylstearyl alcohol 2.0 % by mass peanut oil 5.0 % by mass vaseline oil 3.0 % by mass polyoxyethylene cetylstearyl alcohol (degree of poly ⁇ merization: 20) 2.0 % by mass glycerol 4.0 % by mass methyl p-hydroxybenzoate 0.2 % by mass propyl p-hydroxybenzoate 0.1 % by mass butylhydroxytoluene 0.01% by mass water, demineralized 77.69% by mass

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Cosmetics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Related Child Applications (2)

Publications (1)

Family

ID=10987504

Family Applications (2)

Family Applications Before (1)

Country Status (17)

Families Citing this family (4)

Family Cites Families (6)

• 1995
  • 1995-12-22 HU HU9503728A patent/HUT78139A/hu unknown
• 1996
  • 1996-12-20 WO PCT/HU1996/000081 patent/WO1997023198A1/en not_active Application Discontinuation
  • 1996-12-20 IL IL12498496A patent/IL124984A0/xx unknown
  • 1996-12-20 JP JP52344497A patent/JP2001509129A/ja active Pending
  • 1996-12-20 AU AU11673/97A patent/AU1167397A/en not_active Abandoned
  • 1996-12-20 RU RU99125652/14A patent/RU2197954C2/ru not_active IP Right Cessation
  • 1996-12-20 DE DE69627547T patent/DE69627547T2/de not_active Expired - Fee Related
  • 1996-12-20 PT PT99123365T patent/PT1025838E/pt unknown
  • 1996-12-20 IL IL132854A patent/IL132854A/en not_active IP Right Cessation
  • 1996-12-20 CN CN96199664A patent/CN1207670A/zh active Pending
  • 1996-12-20 EP EP99123365A patent/EP1025838B1/en not_active Expired - Lifetime
  • 1996-12-20 DK DK99123365T patent/DK1025838T3/da active
  • 1996-12-20 ES ES99123365T patent/ES2197565T3/es not_active Expired - Lifetime
  • 1996-12-20 EP EP96942539A patent/EP0869771A1/en not_active Withdrawn
  • 1996-12-20 AT AT99123365T patent/ATE237306T1/de not_active IP Right Cessation
  • 1996-12-20 UA UA98073917A patent/UA46083C2/uk unknown
  • 1996-12-20 CA CA002240505A patent/CA2240505A1/en not_active Abandoned
  • 1996-12-20 KR KR1019980704781A patent/KR19990076669A/ko not_active Application Discontinuation
• 1999
  • 1999-11-24 JP JP33302699A patent/JP3806277B2/ja not_active Expired - Fee Related
  • 1999-11-30 CN CNB991243994A patent/CN1173692C/zh not_active Expired - Fee Related
• 2001
  • 2001-02-09 HK HK01100921A patent/HK1029943A1/xx not_active IP Right Cessation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events